Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
Holding DE:BRM?
Track your performance easily
BRM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€36.42 - €56.00
Previous Close€44.57
Volume135.00
Average Volume (3M)3.93K
Market Cap
€90.98B
Enterprise Value€132.27B
Total Cash (Recent Filing)$6.65B
Total Debt (Recent Filing)$52.39B
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Oct 31, 2024EPS Estimate
€1.44Next Dividend Ex-Date
Oct 04, 2024Dividend Yield4.79%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,027,395,178
10 Day Avg. Volume1,309
30 Day Avg. Volume3,933
Standard Deviation0.07
R-Squared0.05
Alpha0.00524
Financial Highlights & Ratios
Price to Book (P/B)5.28
Price to Sales (P/S)2.17
Price to Cash Flow (P/CF)10.80
P/FCF Ratio12.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit3.85
Enterprise Value/Ebitda38.44
Forecast
1Y Price Target
€43.31Price Target Upside-1.99% Downside
Rating ConsensusHold
Number of Analyst Covering13
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBMY will be initiating a second Ph3 trial of Opdualag in the PDL1 >50% non-squam population.
Drug ApprovalsThere is a high likelihood of FDA approval of KarXT for schizophrenia.
Product GrowthSeveral factors support Breyanzi growth: unconstrained supply, 3 new indications, global expansion, and entry into community setting, supported by a favorable safety profile.
Bears Say
Clinical TrialsThe planned Ph3 trial is questionable as the benefit was driven by less than 50 patients in a subset analysis that showed no significant difference compared to historical data.
Financial PerformanceNo sales growth is expected during 2023-30 due to heavy patent expiration pressures.
Stock PerformanceAfter a 25% share price rally despite little movement in underlying post-2025 fundamentals, an analyst moves to Underweight amidst must-have 2H catalysts and risk of unwind after recent rotation.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.34% Insiders
24.59% Mutual Funds
40.44% Other Institutional Investors
34.62% Public Companies and
Individual Investors
BRM FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €36.42 and its highest was €56.00 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Jul 26, 2024. The company reported €1.867 earnings per share for the quarter, beating the consensus estimate of €1.461 by €0.406.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Overvalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of €0.54 which represents an annual dividend yield of 4.79%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is €1.44.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,027,395,100 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.867 in its last earnings report, beating expectations of €1.461. Following the earnings report the stock price went up 8.335%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 976M.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€43.31 (-1.99% Downside)
€43.31 (-1.99% Downside)
Blogger Sentiment
Bullish
DE:BRM Sentiment 96%
Sector Average 71%
Sector Average 71%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.88%
12-Months-Change
Fundamentals
Return on Equity
-26.70%
Trailing 12-Months
Asset Growth
1.24%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BRM Company Deck
---
BRM Earnings Call
Q2 2024
0:00 / 0:00
---
BRM Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BRM Stock 12 Month Forecast
Average Price Target
€43.31
▼(-1.99% Downside)
Technical Analysis
Bristol-Myers Squibb
―
AstraZeneca
―
Merck & Company
―
Eli Lilly & Co
―
GlaxoSmithKline
―
Best Analysts Covering BRM
1 Year
1 Year Success Rate
14/18 ratings generated profit
1 Year Average Return
+10.82%
assigned a sell rating 5 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +10.82% per trade.
---